Core Viewpoint - The company, Kenji Technology-B (09877), has seen its stock price increase by over 8% following the announcement of regulatory approvals for its medical devices in New Zealand [1] Group 1: Product Approval - Kenji Technology has received registration approval from the New Zealand Medicines and Medical Devices Safety Authority for its transcatheter aortic valve replacement system, Ken-Valve, and its transcatheter tricuspid valve replacement system, LuX-ValvePlus [1] - The company is actively promoting the commercialization of these two products in New Zealand [1] Group 2: Market Recognition - The products, Ken-Valve and LuX-ValvePlus, have gained widespread market recognition due to their design advantages, ongoing clinical trials, and continuous therapy promotion efforts [1] Group 3: Strategic Goals - With the approval of these significant products, the company aims to accelerate the global commercialization process of its product portfolio to further achieve its long-term strategic goals [1]
港股异动 | 健世科技-B(09877)涨超8% 两款核心治疗心脏瓣膜疾病产品获新西兰注册批准